Inify Laboratories AB - Director's Dealing 2022

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, August 19, 2022; Inify Laboratories AB ("Inify") has been

notified that the following transaction has been completed by a close associate

to a primary insider in Inify: Monsun AS, a Norwegian company controlled by

Magne Jordanger, board member and primary insider in Inify, has bought 336,950

shares in Inify at an average price of NOK 7.6 per share. After the transaction,

Monsun AS holds 336,950 shares. Please refer to the attached notification of

trading for further details.

This information is subject to the disclosure requirements in the EU Market

Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian

Securities Trading Act.

For more information, please contact CEO Fredrik Palm ([email protected])

or visit www.inify.com

About Inify Laboratories AB (publ)

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory

services within histopathology. Fully digital, standardized and AI- supported

workflow is applied to optimize quality and response times, initially for

prostate cancer. The concept is scalable and extendible to other diagnosis. The

company origins from ContextVision and became independent in February 2022. The

company is based in Sweden and listed on Euronext Growth Oslo under the ticker

INIFY

AI assistant